ALEMBIC | PROCTER & GAMBLE HEALTH | ALEMBIC/ PROCTER & GAMBLE HEALTH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 31.2 | 34.4 | 90.6% | View Chart |
P/BV | x | 1.1 | 10.5 | 10.9% | View Chart |
Dividend Yield | % | 2.4 | 2.0 | 117.5% |
ALEMBIC PROCTER & GAMBLE HEALTH |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-23 |
PROCTER & GAMBLE HEALTH Jun-23 |
ALEMBIC/ PROCTER & GAMBLE HEALTH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 87 | 5,366 | 1.6% | |
Low | Rs | 56 | 3,883 | 1.4% | |
Sales per share (Unadj.) | Rs | 5.0 | 740.7 | 0.7% | |
Earnings per share (Unadj.) | Rs | 3.1 | 138.2 | 2.3% | |
Cash flow per share (Unadj.) | Rs | 3.4 | 155.2 | 2.2% | |
Dividends per share (Unadj.) | Rs | 2.20 | 95.00 | 2.3% | |
Avg Dividend yield | % | 3.1 | 2.1 | 150.3% | |
Book value per share (Unadj.) | Rs | 80.9 | 447.6 | 18.1% | |
Shares outstanding (eoy) | m | 256.78 | 16.60 | 1,546.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 14.4 | 6.2 | 230.4% | |
Avg P/E ratio | x | 22.7 | 33.5 | 67.9% | |
P/CF ratio (eoy) | x | 21.0 | 29.8 | 70.3% | |
Price / Book Value ratio | x | 0.9 | 10.3 | 8.5% | |
Dividend payout | % | 70.1 | 68.7 | 102.0% | |
Avg Mkt Cap | Rs m | 18,298 | 76,761 | 23.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 240 | 2,062 | 11.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,272 | 12,296 | 10.3% | |
Other income | Rs m | 643 | 184 | 349.4% | |
Total revenues | Rs m | 1,915 | 12,480 | 15.3% | |
Gross profit | Rs m | 297 | 3,247 | 9.2% | |
Depreciation | Rs m | 67 | 281 | 23.9% | |
Interest | Rs m | 5 | 8 | 60.4% | |
Profit before tax | Rs m | 868 | 3,142 | 27.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 62 | 847 | 7.3% | |
Profit after tax | Rs m | 806 | 2,295 | 35.1% | |
Gross profit margin | % | 23.4 | 26.4 | 88.5% | |
Effective tax rate | % | 7.1 | 27.0 | 26.4% | |
Net profit margin | % | 63.4 | 18.7 | 339.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,721 | 11,713 | 14.7% | |
Current liabilities | Rs m | 838 | 6,791 | 12.3% | |
Net working cap to sales | % | 69.4 | 40.0 | 173.4% | |
Current ratio | x | 2.1 | 1.7 | 119.1% | |
Inventory Days | Days | 5,038 | 263 | 1,917.4% | |
Debtors Days | Days | 673 | 343 | 195.8% | |
Net fixed assets | Rs m | 20,324 | 10,617 | 191.4% | |
Share capital | Rs m | 514 | 166 | 309.4% | |
"Free" reserves | Rs m | 20,267 | 7,265 | 279.0% | |
Net worth | Rs m | 20,780 | 7,431 | 279.7% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,046 | 22,330 | 98.7% | |
Interest coverage | x | 187.7 | 409.1 | 45.9% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.1 | 0.6 | 10.5% | |
Return on assets | % | 3.7 | 10.3 | 35.7% | |
Return on equity | % | 3.9 | 30.9 | 12.6% | |
Return on capital | % | 4.2 | 42.4 | 9.9% | |
Exports to sales | % | 1.2 | 0 | - | |
Imports to sales | % | 2.4 | 13.1 | 18.0% | |
Exports (fob) | Rs m | 16 | NA | - | |
Imports (cif) | Rs m | 30 | 1,605 | 1.9% | |
Fx inflow | Rs m | 16 | 1,465 | 1.1% | |
Fx outflow | Rs m | 30 | 1,605 | 1.9% | |
Net fx | Rs m | -14 | -140 | 10.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 389 | 2,360 | 16.5% | |
From Investments | Rs m | 73 | -215 | -33.9% | |
From Financial Activity | Rs m | -464 | -985 | 47.1% | |
Net Cashflow | Rs m | -2 | 1,160 | -0.2% |
Indian Promoters | % | 70.9 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 51.8 | - | |
Indian inst/Mut Fund | % | 1.1 | 20.0 | 5.6% | |
FIIs | % | 1.1 | 6.2 | 17.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 29.1 | 48.2 | 60.4% | |
Shareholders | 99,130 | 56,778 | 174.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ALEMBIC | Procter & Gamble Health | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.49% | 0.14% | -0.44% |
1-Month | 15.19% | -3.36% | 2.15% |
1-Year | 49.42% | -0.17% | 49.82% |
3-Year CAGR | -2.69% | -9.52% | 14.21% |
5-Year CAGR | 16.83% | 4.46% | 19.19% |
* Compound Annual Growth Rate
Here are more details on the ALEMBIC share price and the Procter & Gamble Health share price.
Moving on to shareholding structures...
The promoters of ALEMBIC hold a 70.9% stake in the company. In case of Procter & Gamble Health the stake stands at 51.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ALEMBIC and the shareholding pattern of Procter & Gamble Health.
Finally, a word on dividends...
In the most recent financial year, ALEMBIC paid a dividend of Rs 2.2 per share. This amounted to a Dividend Payout ratio of 70.1%.
Procter & Gamble Health paid Rs 95.0, and its dividend payout ratio stood at 68.7%.
You may visit here to review the dividend history of ALEMBIC, and the dividend history of Procter & Gamble Health.
For a sector overview, read our pharmaceuticals sector report.
After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.